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Background
Signaling by intracellular cGMP and cGMP-dependent
protein kinase I (cGKI) is the major pathway in vascular
smooth muscle, by which endothelial NO regulates vascu-
lar tone. The most important targets of cGKI include the
myosin-interacting subunit of myosin phosphatase 1, the
regulator of G-protein signaling 2, the inositol receptor
associated cGKI-substrate, and the BK channel. Recent
evidence suggest that TrpC channels are also targets of
cGKI in smooth muscle and mediate, at least partially, the
relaxant effects of cGMP.
Results
We tested this new concept by investigating the role of
cGMP/cGKI signaling on vascular tone and peripheral
resistance using cGKI-, TrpC6-, and TrpC3-knock-out
mice. We found no differences in the response to alpha-
adrenergic stimulation with respect to the contractility of
thoracic aorta or to the increase in peripheral resistance
using preparations from the knock-out models. Activation
of cGKI by 8-Br-cGMP diminished aortic tone and periph-
eral resistance to a similar extent in control, TrpC6-/-, and
TrpC3-/- mice. No effect of 8-Br-cGMP was observed in
preparations from smooth-muscle specific cGKI-/- mice.
Conclusion
The results suggest that cGMP/cGKI signaling in aorta
and peripheral vessels from mice does not require
TrpC6 or TrpC3 channels.
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